



MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH CIRCULAR No. 51/2017

DH 920/2017

25th July 2017

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Azacitidine 100mg Vials

As part of Government's policy to increase the number of oncology medicines on the Government Formulary List, Azacitidine is the fourth oncology medicine being introduced in 2017.

As from Monday 24th July 2017, patients suffering from Acute Myelocytic Leukaemia (AML) and Myelodysplastic Syndrome (MDS) who are not eligible for haematopoietic stem cell transplantation and/or chemotherapy will be benefitting from Azacitidine treatment.

Azacitidine 100mg vials can be prescribed by Consultant Haematologists and treatment is administered on an in-patient basis. Kindly refer to protocol 301 (Annex 1) for more information.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer

Azacitidine 100mg Vials

Prescriber Criteria: Consultant Haematologist

In-patient use:

1. Acute Myelocytic Leukaemia (AML)

Reserved for patients with AML who:

- Are not eligible for haematopoietic stem cell transplantation AND/OR
- Are over 70 years of age and/or are unable to tolerate intensive chemotherapy

2. Myelodysplastic Syndrome (MDS)

Reserved for patients who are suffering from intermediate and high-risk MDS who are not eligible for aggressive chemotherapy

Duration of Approval:

6 months